[Is aztreonam could become "a challenger" for treatment of Gram negative infections? May be an answer from microbiological data: in vitro study including 36,485 strains of enterobacteria and Pseudomonas].
During 6 years, 2000 to 2006, we looked for evolution of antimicrobial resistance to beta-lactams of clinical isolates from patients with Gram negative infections. In vitro susceptibilities to piperacillin+tazobactam, ceftazidime, and aztreonam were followed along the period. Enterobacteriaceae of group 1 to 3 represent 24,884 strains and Pseudomonas spp. 11601. The global sensitivity of aztreonam was 85%, 87.1% for ceftazidime and 88.8% for pieracilline-tazobactam. Of course, aztreonam spectrum of activity is dedicated to Gram negative bacteria only but it is known to have a great penetration ratio in tissues and a half-live observed up to 6 times higher than in serum in experimental models. Antimicrobial rotation strategy is recommended in the prudent use of antibiotics. It seems that in our hospital a consistent increase of the use of aztreonam might be possible and proposed without increasing risk for infection control practices according to the microbiological laboratory results.
Honderlick
P
P
Service de Microbiologie, Hôpital Foch, 40, rue Worth, BP 92151, Suresnes, France. p.honderlick@hopital-foch.org
Gravisse
J
J
Dardelle
D
D
Cahen
P
P
D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D001398:Aztreonam / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D024881:Drug Resistance, Bacterial; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy*; D006207:Half-Life; D006801:Humans; D008826:Microbial Sensitivity Tests; D010878:Piperacillin / Q000494:pharmacology; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D012680:Sensitivity and Specificity
D000900:Anti-Bacterial Agents; D001398:Aztreonam; D010878:Piperacillin